Posted by admin on May 11th, 2022

Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) CEO James W. Green purchased 30,000 shares of the business’s stock in a transaction on Friday, May 6th. The shares were acquired at an average cost of $3.78 per share, with a total value of $113,400.00. Following the acquisition, the chief executive officer now directly owns 2,309,955 shares in the company, valued at $8,731,629.90. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

HBIO stock opened at $3.58 on Wednesday. The company has a quick ratio of 1.34, a current ratio of 2.18 and a debt-to-equity ratio of 0.61. The company has a market cap of $147.64 million, a PE ratio of -22.37 and a beta of 1.84. The stock’s fifty day moving average price is $5.72. Harvard Bioscience, Inc. has a fifty-two week low of $3.36 and a fifty-two week high of $8.75.

Harvard Bioscience (NASDAQ:HBIO – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.01). Harvard Bioscience had a positive return on equity of 9.06% and a negative net margin of 5.38%. During the same period in the prior year, the firm posted $0.03 EPS. Equities research analysts expect that Harvard Bioscience, Inc. will post 0.24 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of HBIO. AMH Equity Ltd bought a new position in Harvard Bioscience during the 4th quarter worth $5,640,000. B. Riley Asset Management LLC bought a new position in shares of Harvard Bioscience in the fourth quarter worth $4,176,000. Meros Investment Management LP bought a new position in shares of Harvard Bioscience in the fourth quarter worth $3,049,000. BlackRock Inc. increased its position in shares of Harvard Bioscience by 11.9% in the fourth quarter. BlackRock Inc. now owns 3,063,190 shares of the medical instruments supplier’s stock worth $21,595,000 after purchasing an additional 325,723 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Harvard Bioscience in the fourth quarter worth $1,610,000. Hedge funds and other institutional investors own 72.75% of the company’s stock.

Several brokerages have issued reports on HBIO. Zacks Investment Research raised Harvard Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday. StockNews.com initiated coverage on Harvard Bioscience in a report on Thursday, March 31st. They set a “hold” rating for the company.

Harvard Bioscience Company Profile (Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Insider Selling: Alphabet Inc. (NASDAQ:GOOGL) Director Sells 31 Shares of Stock

Insider Selling: Simpson Manufacturing Co., Inc. (NYSE:SSD) Director Sells 1,180 Shares of Stock